TABLE 2.
SARS-CoV-2 IgG antibody and self-reported COVID-19 prevalence, prevalence ratios (PR), and 95% confidence intervals (CI) by study group, North Carolina, 2021 to 2022a
| Outcome | Number positive/total (%) | Crude PR (95% CI) |
|---|---|---|
| Antibody assay results | ||
| SARS-CoV-2 infection-induced IgG (positive for both N and RBD) | ||
| ILO vs: | 46/73 (63) | |
| ILON (reference) | 36/84 (42.9) | 1.47 (1.05–2.07) |
| Metro (reference) | 37/76 (48.7) | 1.29 (0.95–1.76) |
| ILON and metro (reference) | 73/160 (45.6) | 1.38 (1.06–1.8) |
| SARS-CoV-2 infection- and/or vaccination- induced IgG (positive for RBD) | ||
| ILO vs: | 57/73 (78.1) | |
| ILON (reference) | 53/84 (63.1) | 1.24 (1–1.53) |
| Metro (reference) | 59/76 (77.6) | 1.01 (0.85–1.19) |
| ILON and metro (reference) | 112/160 (70) | 1.12 (0.95–1.31) |
| Self-reported COVID-19 | ||
| At least one symptom of COVID-19b | ||
| ILO vs: | 48/73 (65.8) | |
| ILON (reference) | 40/84 (47.6) | 1.38 (1.03–1.85) |
| Metro (reference) | 39/76 (51.3) | 1.28 (0.96–1.71) |
| ILON and metro (reference) | 79/160 (49.4) | 1.33 (1.05–1.7) |
| At least two symptoms of COVID-19b | ||
| ILO vs: | 40/73 (54.8) | |
| ILON (reference) | 29/84 (34.5) | 1.59 (1.08–2.33) |
| Metro (reference) | 35/76 (46.1) | 1.19 (0.85–1.67) |
| ILON and metro (reference) | 64/160 (40) | 1.37 (1.02–1.84) |
| Ever thought you had COVID-19 | ||
| ILO vs: | 19/73 (26) | |
| ILON (reference) | 16/84 (19) | 1.37 (0.76–2.47) |
| Metro (reference) | 16/76 (21.1) | 1.24 (0.67–2.28) |
| ILON and metro (reference) | 32/160 (20) | 1.3 (0.78–2.17) |
| Ever tested positive for SARS-CoV-2 | ||
| ILO vs: | 10/73 (13.7) | |
| ILON (reference) | 10/84 (11.9) | 0.96 (0.45–2.02) |
| Metro (reference) | 16/76 (21.1) | 0.67 (0.34–1.29) |
| ILON and metro (reference) | 26/160 (16.2) | 0.78 (0.42–1.45) |
ILO, study participants living in a household with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON, participants living near these facilities without any known occupational exposure to livestock; metro, participants living in metropolitan areas.
Listed by CDC: fever or chills; cough; shortness of breath or difficulty breathing; lack of energy or general tired feeling; muscle or body aches; headache; new loss of taste or smell; sore throat, congestion, or runny nose; feeling sick to your stomach or vomiting, diarrhea; abdominal pain; skin rash (25); since 1 February 2020.